The U.S. Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) in combination with chemotherapy for adult and pediatric patients aged 12 and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). This decision represents a significant advancement in cancer therapy, expanding frontline treatment options and improving potential survival outcomes for patients facing this challenging disease.
The new regimen combines nivolumab with AVD chemotherapy, which includes doxorubicin, vinblastine, and dacarbazine. Previously, nivolumab had been reserved for relapsed or refractory cases, but this approval establishes its role as a first-line therapy, marking a notable shift in clinical practice.
Clinical data demonstrated that nivolumab plus AVD substantially improved progression-free survival compared with prior frontline options, such as brentuximab vedotin plus AVD. In the CA209‑8UT (SWOG 1826) trial, which enrolled nearly 1,000 participants worldwide, patients receiving nivolumab with chemotherapy had a hazard ratio of 0.42, indicating a significant reduction in the risk of disease progression. At the median follow-up, progression-free survival had not yet been reached, suggesting durable disease control.
Furthermore, safety outcomes were manageable. Serious treatment-emergent adverse events occurred in 39% of participants, while immune-mediated reactions were reported in 9%, and grade 3–4 immune toxicities remained uncommon at 2.7%. These results reinforce nivolumab’s benefit-risk profile when combined with frontline chemotherapy.
Under the new approval, nivolumab also retains full approval for adults with relapsed or refractory Hodgkin lymphoma following autologous stem cell transplantation and subsequent brentuximab vedotin therapy, or after progression on multiple prior systemic regimens. This expanded indication reflects the FDA’s confidence in nivolumab’s efficacy across multiple treatment settings.
Mechanistically, nivolumab is a PD-1 immune checkpoint inhibitor. By blocking PD-1, it restores T-cell activity against cancer cells, harnessing the immune system to target malignant lymphocytes. The integration of immunotherapy into frontline care represents a paradigm shift, particularly for aggressive hematologic malignancies.
Healthcare providers now have clear administration guidance. Adults receive 240 mg of nivolumab intravenously per cycle, alongside AVD on Days 1 and 15 of each 28-day cycle, for up to six cycles. Pediatric dosing is weight-based. Prophylactic granulocyte-colony stimulating factor (G-CSF) is recommended from the first cycle to support immunity and reduce infection risk.
The FDA reviewed this application under Project Orbis, which facilitates concurrent oncology evaluations with partner agencies, including the Israeli Ministry of Health, the Australian Therapeutic Goods Administration, Health Canada, and Swissmedic. This collaborative approach accelerated regulatory assessment and strengthened international alignment for new cancer therapies.
According to the American Cancer Society, an estimated 8,920 new Hodgkin lymphoma cases will be diagnosed in the United States in 2026, including 4,890 males and 4,030 females. Approximately 1,100 deaths are projected, with 680 among men and 420 among women. These statistics highlight the continuing need for innovative therapies such as nivolumab to improve patient outcomes and reduce mortality.
Experts emphasize that combining immunotherapy with standard chemotherapy may improve long-term disease control while maintaining a manageable safety profile. Early use of nivolumab could establish a new standard of care for advanced Hodgkin lymphoma, providing hope for patients who previously faced limited frontline options.
Clinicians should remain vigilant in monitoring immune-related toxicities and are encouraged to report serious adverse events to the FDA’s MedWatch program. Ongoing real-world data will further inform the long-term safety and effectiveness of nivolumab in this setting.
Overall, the FDA’s approval of nivolumab with chemotherapy for previously untreated Hodgkin lymphoma represents a significant milestone in oncology. By integrating immunotherapy into initial treatment strategies, patients now have access to therapies that harness the immune system to improve progression-free survival, enhance long-term disease control, and potentially reduce mortality. This advancement underscores the growing role of PD-1 inhibitors in reshaping modern cancer care and delivering hope to patients and families affected by Hodgkin lymphoma.
